Efficacy and Toxicity of Factor Xa Inhibitors
Venous thromboembolism (VTE) is a serious disease that is often neglected, and effective and safe antithrombotic treatments are a public health priority. New antithrombotics such as rivaroxaban, apixaban, betrixaban, edoxaban, darexaban, TAK-442, LY517717, eribaxaban, otamixaban are being developed...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2013-02-01
|
| Series: | Journal of Pharmacy & Pharmaceutical Sciences |
| Online Access: | https://journals.library.ualberta.ca/jpps/index.php/JPPS/article/view/18644 |
| _version_ | 1797710926704541696 |
|---|---|
| author | Maryna Bondarenko Christophe Curti Marc Montana Pascal Rathelot Patrice Vanelle |
| author_facet | Maryna Bondarenko Christophe Curti Marc Montana Pascal Rathelot Patrice Vanelle |
| author_sort | Maryna Bondarenko |
| collection | DOAJ |
| description | Venous thromboembolism (VTE) is a serious disease that is often neglected, and effective and safe antithrombotic treatments are a public health priority. New antithrombotics such as rivaroxaban, apixaban, betrixaban, edoxaban, darexaban, TAK-442, LY517717, eribaxaban, otamixaban are being developed to overcome current therapeutic limitations. The new oral anticoagulants and parenteral otamixaban are under evaluation in clinical trials for VTE treatment, for VTE prevention in orthopedic surgery, for stroke prevention in patients with atrial fibrillation and for cardiovascular event prevention in patients with acute coronary syndrome. These antithrombotic agents directly and selectively inhibit factor Xa, and do not require coagulation monitoring and dose adjustment. Several of these drugs have shown promising results and have the potential to either replace or act as alternatives to traditional anticoagulants (heparins, vitamin K antagonists).
This article is open to POST-PUBLICATION REVIEW. Registered readers (see “For Readers”) may comment by clicking on ABSTRACT on the issue’s contents page. |
| first_indexed | 2024-03-12T06:59:24Z |
| format | Article |
| id | doaj.art-c99535f8568b4cde988db0a404215714 |
| institution | Directory Open Access Journal |
| issn | 1482-1826 |
| language | English |
| last_indexed | 2024-03-12T06:59:24Z |
| publishDate | 2013-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Journal of Pharmacy & Pharmaceutical Sciences |
| spelling | doaj.art-c99535f8568b4cde988db0a4042157142023-09-02T23:50:57ZengFrontiers Media S.A.Journal of Pharmacy & Pharmaceutical Sciences1482-18262013-02-0116110.18433/J33P49Efficacy and Toxicity of Factor Xa InhibitorsMaryna Bondarenko0Christophe Curti1Marc Montana2Pascal Rathelot3Patrice Vanelle4Assistance Publique - Hôpitaux de Marseille (AP-HM), Service de la pharmacie à usage intérieur de l’hôpital Nord, Marseille, FranceAix-Marseille Université, CNRS, Institut de Chimie Radicalaire ICR, UMR 7273, Laboratoire de Pharmaco-Chimie Radicalaire, Marseille, France Assistance Publique - Hôpitaux de Marseille (AP-HM), Service Central de la Qualité et de l’Information Pharmaceutiques, Marseille, FranceAix-Marseille Université, CNRS, Institut de Chimie Radicalaire ICR, UMR 7273, Laboratoire de Pharmaco-Chimie Radicalaire, Marseille, France Assistance Publique - Hôpitaux de Marseille (AP-HM), Oncopharma, Marseille, FranceAix-Marseille Université, CNRS, Institut de Chimie Radicalaire ICR, UMR 7273, Laboratoire de Pharmaco-Chimie Radicalaire, Marseille, France Assistance Publique - Hôpitaux de Marseille (AP-HM), Service Central de la Qualité et de l’Information Pharmaceutiques, Marseille, FranceAix-Marseille Université, CNRS, Institut de Chimie Radicalaire ICR, UMR 7273, Laboratoire de Pharmaco-Chimie Radicalaire, Marseille, France Assistance Publique - Hôpitaux de Marseille (AP-HM), Service Central de la Qualité et de l’Information Pharmaceutiques, Marseille, FranceVenous thromboembolism (VTE) is a serious disease that is often neglected, and effective and safe antithrombotic treatments are a public health priority. New antithrombotics such as rivaroxaban, apixaban, betrixaban, edoxaban, darexaban, TAK-442, LY517717, eribaxaban, otamixaban are being developed to overcome current therapeutic limitations. The new oral anticoagulants and parenteral otamixaban are under evaluation in clinical trials for VTE treatment, for VTE prevention in orthopedic surgery, for stroke prevention in patients with atrial fibrillation and for cardiovascular event prevention in patients with acute coronary syndrome. These antithrombotic agents directly and selectively inhibit factor Xa, and do not require coagulation monitoring and dose adjustment. Several of these drugs have shown promising results and have the potential to either replace or act as alternatives to traditional anticoagulants (heparins, vitamin K antagonists). This article is open to POST-PUBLICATION REVIEW. Registered readers (see “For Readers”) may comment by clicking on ABSTRACT on the issue’s contents page.https://journals.library.ualberta.ca/jpps/index.php/JPPS/article/view/18644 |
| spellingShingle | Maryna Bondarenko Christophe Curti Marc Montana Pascal Rathelot Patrice Vanelle Efficacy and Toxicity of Factor Xa Inhibitors Journal of Pharmacy & Pharmaceutical Sciences |
| title | Efficacy and Toxicity of Factor Xa Inhibitors |
| title_full | Efficacy and Toxicity of Factor Xa Inhibitors |
| title_fullStr | Efficacy and Toxicity of Factor Xa Inhibitors |
| title_full_unstemmed | Efficacy and Toxicity of Factor Xa Inhibitors |
| title_short | Efficacy and Toxicity of Factor Xa Inhibitors |
| title_sort | efficacy and toxicity of factor xa inhibitors |
| url | https://journals.library.ualberta.ca/jpps/index.php/JPPS/article/view/18644 |
| work_keys_str_mv | AT marynabondarenko efficacyandtoxicityoffactorxainhibitors AT christophecurti efficacyandtoxicityoffactorxainhibitors AT marcmontana efficacyandtoxicityoffactorxainhibitors AT pascalrathelot efficacyandtoxicityoffactorxainhibitors AT patricevanelle efficacyandtoxicityoffactorxainhibitors |